Secarna Pharmaceuticals adds leading expert to Scientific Advisory Board with appointment of Prof. Dr. Vignali
- Prof. Dr. Dario A.A. Vignali brings vast knowledge from groundbreaking cancer research work in immune regulation and the immunosuppressive tumor microenvironment
- His expertise in the field of immuno-oncology and in particular NRP1, the target of Secarna’s lead asset, SECN-15, will help translate the Company’s scientific discoveries into significant clinical strategies
- Prof. Vignali joins current SAB members Prof. Dr. Alexander M.M. Eggermont and Prof. Dr. Alfred Zippelius, both cancer research key opinion leaders
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR
- Data will showcase SECN-15’s potential to significantly improve the efficacy of immune checkpoint inhibitors
- Secarna is preparing for first-in-human trials to start mid-2026 to further explore this promising combination therapeutic strategy
Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Officer
Martinsried (Munich), Germany, October 31, 2024 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the promotion of Konstantin Petropoulos, PhD, MBA, to Chief Executive Officer. He has served as the Company’s Chief Business Officer since June 2023. Alexander Gebauer, MD, PhD, is stepping down with immediate effect to focus his efforts on another company, Galimedix Therapeutics, that he has co-founded and is leading. He will continue to support Dr. Petropoulos in his new role to ensure a smooth transition.
American Association for Cancer Research (AACR) 2025
LSX World Congress Europe
Latest News & Events
Secarna Pharmaceuticals adds leading expert to Scientific Advisory Board with appointment of Prof. Dr. Vignali
- Prof. Dr. Dario A.A. Vignali brings vast knowledge from groundbreaking cancer research work in immune regulation and the immunosuppressive tumor microenvironment
- His expertise in the field of immuno-oncology and in particular NRP1, the target of Secarna’s lead asset, SECN-15, will help translate the Company’s scientific discoveries into significant clinical strategies
- Prof. Vignali joins current SAB members Prof. Dr. Alexander M.M. Eggermont and Prof. Dr. Alfred Zippelius, both cancer research key opinion leaders
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR
- Data will showcase SECN-15’s potential to significantly improve the efficacy of immune checkpoint inhibitors
- Secarna is preparing for first-in-human trials to start mid-2026 to further explore this promising combination therapeutic strategy
Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Officer
Martinsried (Munich), Germany, October 31, 2024 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the promotion of Konstantin Petropoulos, PhD, MBA, to Chief Executive Officer. He has served as the Company’s Chief Business Officer since June 2023. Alexander Gebauer, MD, PhD, is stepping down with immediate effect to focus his efforts on another company, Galimedix Therapeutics, that he has co-founded and is leading. He will continue to support Dr. Petropoulos in his new role to ensure a smooth transition.